Why are the most effective weight-loss drugs in a generation still so hard to get covered? A new analysis pinpoints the paradox at the heart of the GLP-1 story: the drugs are genuinely cost-effective for an individual patient, but the number of people who qualify makes paying for all of them almost impossible.
The math behind the problem
Roughly 40% of American adults have obesity. That enormous eligible population is exactly what makes broad insurance coverage so daunting. Researchers at the University of Mississippi, writing in the Journal of Managed Care and Specialty Pharmacy, measured GLP-1 spending against a common yardstick: the Institute for Clinical and Economic Review's (ICER) budget-impact threshold of about $821 million a year. GLP-1 costs, they found, “blow way past that threshold.”
“GLP-1s provide tremendous value to society, but the budget impact is still massive” because so many people are eligible, said researcher Sujith Ramachandran.
Two extra complications
The picture is muddied further by two facts. First, many patients stop taking the drugs within the first year, which undercuts the long-term benefit. Second, the promised long-term savings from treating obesity haven't yet been proven in the available data. Trials that pair the medication with lifestyle support — dietitian access, gym membership — show the best results, but that adds cost too.
Why it matters
This is the invisible force behind the coverage fights, prior-authorization hurdles, and out-of-pocket costs patients keep running into. It isn't that the drugs don't work — it's that a treatment eligible to tens of millions strains any budget. Solving access will likely require lower prices, smarter targeting of who benefits most, or new payment models, not just more demand. This article is general information, not medical or financial advice.